AIThe Next Webabout 2 hours ago
Bios Life exits stealth with $25M and Tempus alliance
1 min read
Bios Life emerged from stealth with $25M in seed funding led by Redmile, Vsquared Ventures, and Kindred Capital. The Boston company plans AI-driven continuous cancer surveillance using Tempus data and BioNTech-InstaDeep's Nucleotide Transformer, targeting over 40 million Americans at risk or surviving cancer. Launch is slated for the second half of 2026.
Level
Hype check
Tap to vote and see what everyone thinks.
Summary by ByteBrief
